In vitro modelling of Alzheimer's disease: Degeneration and cell death induced by viral delivery of amyloid and tau

Experimental Neurology

Volumn 229, Issue 2, 2011, Pages 226-237

  Stoppelkamp, Sandra ^a,b   Bell, Helen S ^a,b   Palacios Filardo, Jon ^a,b   Shewan, Derryck A ^a   Riedel, Gernot ^a   Platt, Bettina ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b INSTITUTO DE NEUROCIENCIAS   (Spain)

Author keywords

APP; Calcium homeostasis; Culture; DRG; Drug testing; Hippocampus; Rat; Tau

Indexed keywords

BETA SECRETASE INHIBITOR; CAFFEINE; CALCIUM ION; CLIOQUINOL; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA SECRETASE INHIBITOR; LITHIUM;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; APP GENE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NERVE CELL LESION; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE EXCITABILITY; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SPINAL GANGLION; TAU GENE; TRANSGENE;

ADENOVIRIDAE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; CALCIUM; CELL DEATH; CELL LINE; CELLS, CULTURED; DENDRITES; GANGLIA, SPINAL; GENETIC VECTORS; HIPPOCAMPUS; NERVE DEGENERATION; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; TAU PROTEINS; TRANSDUCTION, GENETIC;

EID: 79956122555     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.01.018     Document Type: Article

References (75)

1. Arendash G.W., Schleif W., Rezai-Zadeh K., Jackson E.K., Zacharia L.C., Cracchiolo J.R., Shippy D., Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 2006, 142:941-952.
2. Arendash G.W., Mori T., Cao C., Mamcarz M., Runfeldt M., Dickson A., Rezai-Zadeh K., Tan J., Citron B.A., Lin X., Echeverria V., Potter H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J. Alzheimers Dis. 2009, 17:661-680.
3. Atamna H., Nguyen A., Schultz C., Boyle K., Newberry J., Kato H., Ames B.N. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J. 2008, 22:703-712.
4. Bi X., Gall C.M., Zhou J., Lynch G. Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 2002, 112:827-840.
5. Caccamo A., Oddo S., Tran L.X., LaFerla F.M. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 2007, 170:1669-1675.
6. Callaway N.L., Riha P.D., Bruchey A.K., Munshi Z., Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol. Biochem. Behav. 2004, 77:175-181.
7. Chang K.A., Kim H.S., Ha T.Y., Ha J.W., Shin K.Y., Jeong Y.H., Lee J.P., Park C.H., Kim S., Baik T.K., Suh Y.H. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol. Cell. Biol. 2006, 26:4327-4338.
8. Citron M., Vigo-Pelfrey C., Teplow D.B., Miller C., Schenk D., Johnston J., Winblad B., Venizelos N., Lannfelt L., Selkoe D.J. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc. Natl Acad. Sci. USA 1994, 91:11993-11997.
9. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
10. Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J. Cell Biol. 1998, 143:777-794.
11. Faux N.G., Ritchie C.W., Gunn A., Rembach A., Tsatsanis A., Bedo J., Harrison J., Lannfelt L., Blennow K., Zetterberg H., Ingelsson M., Masters C.L., Tanzi R.E., Cummings J.L., Herd C.M., Bush A.I. PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J. Alzheimers Dis. 2010, 20:509-516.
12. Goedert M. Tau gene mutations and their effects. Mov. Disord. 2005, 20(Suppl 12):S45-S52.
13. Goldsbury C., Mocanu M.-M., Thies E., Kaether C., Haass C., Keller P., Biernat J., Mandelkow E., Mandelkow E.-M. Inhibition of APP trafficking by Tau protein does not increase the generation of amyloid-beta peptides. Traffic 2006, 7:873-888.
14. Gralle M., Ferreira S.T. Structure and function of the human amyloid precursor protein: the whole is more than the sum of its parts. Prog. Neurobiol. 2007, 82:11-32.
15. Hampel H., Ewers M., Burger K., Annas P., Mortberg A., Bogstedt A., Frolich L., Schroder J., Schonknecht P., Riepe M.W., Kraft I., Gasser T., Leyhe T., Moller H.J., Kurz A., Basun H. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry 2009, 70:922-931.
16. Hattori M., Sugino E., Minoura K., In Y., Sumida M., Taniguchi T., Tomoo K., Ishida T. Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain. Biochem. Biophys. Res. Commun. 2008, 374:158-163.
17. Hinners I., Hill A., Otto U., Michalsky A., Mack T.G., Striggow F. Tau kinase inhibitors protect hippocampal synapses despite of insoluble tau accumulation. Mol. Cell. Neurosci. 2008, 37:559-567.
18. Hou J.F., Cui J., Yu L.C., Zhang Y. Intracellular amyloid induces impairments on electrophysiological properties of cultured human neurons. Neurosci. Lett. 2009, 462:294-299.
19. Iijima K., Ando K., Takeda S., Satoh Y., Seki T., Itohara S., Greengard P., Kirino Y., Nairn A.C., Suzuki T. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J. Neurochem. 2000, 75:1085-1091.
20. Jope R.S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 2003, 24:441-443.
21. Keil U., Bonert A., Marques C.A., Scherping I., Weyermann J., Strosznajder J.B., Muller-Spahn F., Haass C., Czech C., Pradier L., Muller W.E., Eckert A. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem. 2004, 279:50310-50320.
22. Kienlen-Campard P., Miolet S., Tasiaux B., Octave J.N. Intracellular amyloid-beta 1-42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis. J. Biol. Chem. 2002, 277:15666-15670.
23. Kloskowska E., Malkiewicz K., Winblad B., Benedikz E., Bruton J.D. APPswe mutation increases the frequency of spontaneous Ca2+-oscillations in rat hippocampal neurons. Neurosci. Lett. 2008, 436:250-254.
24. Kong G.K., Miles L.A., Crespi G.A., Morton C.J., Ng H.L., Barnham K.J., McKinstry W.J., Cappai R., Parker M.W. Copper binding to the Alzheimer's disease amyloid precursor protein. Eur. Biophys. J. 2008, 37:269-279.
25. Koo E.H., Squazzo S.L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 1994, 269:17386-17389.
26. Koss D.J., Hindley K.P., Riedel G., Platt B. Modulation of hippocampal calcium signalling and plasticity by serine/threonine protein phosphatases. J. Neurochem. 2007, 102:1009-1023.
27. Kumar-Singh S., Julliams A., Nuydens R., Ceuterick C., Labeur C., Serneels S., Vennekens K., Van Osta P., Geerts H., De Strooper B., Van Broeckhoven C. In vitro studies of Flemish, Dutch, and wild-type beta-amyloid provide evidence for two-staged neurotoxicity. Neurobiol. Dis. 2002, 11:330-340.
28. Lakatos A., Zsigo E., Hollender D., Nagy N.V., Fulop L., Simon D., Bozso Z., Kiss T. Two pyridine derivatives as potential Cu(II) and Zn(II) chelators in therapy for Alzheimer's disease. Dalton Trans. 2010, 39:1302-1315.
29. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C.L., Targum S., Bush A.I., Murdoch R., Wilson J., Ritchie C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008, 7:779-786. PBT2-201-EURO study group.
30. Lee M.S., Kao S.C., Lemere C.A., Xia W., Tseng H.C., Zhou Y., Neve R., Ahlijanian M.K., Tsai L.H. APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. 2003, 163:83-95.
31. Leroy K., Ando K., Heraud C., Yilmaz Z., Authelet M., Boeynaems J.M., Buee L., De Decker R., Brion J.P. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J. Alzheimers Dis. 2010, 19:705-719.
32. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
33. Leyhe T., Eschweiler G.W., Stransky E., Gasser T., Annas P., Basun H., Laske C. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J. Alzheimers Dis. 2009, 16:649-656.
34. Lo D.C., McAllister A.K., Katz L.C. Neuronal transfection in brain slices using particle-mediated gene transfer. Neuron 1994, 13:1263-1268.
35. Louneva N., Cohen J.W., Han L.Y., Talbot K., Wilson R.S., Bennett D.A., Trojanowski J.Q., Arnold S.E. Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. Am. J. Pathol. 2008, 173:1488-1495.
36. Luo J.J., Wallace W., Riccioni T., Ingram D.K., Roth G.S., Kusiak J.W. Death of PC12 cells and hippocampal neurons induced by adenoviral-mediated FAD human amyloid precursor protein gene expression. J. Neurosci. Res. 1999, 55:629-642.
37. Macq A.F., Czech C., Essalmani R., Brion J.P., Maron A., Mercken L., Pradier L., Octave J.N. The long term adenoviral expression of the human amyloid precursor protein shows different secretase activities in rat cortical neurons and astrocytes. J. Biol. Chem. 1998, 273:28931-28936.
38. Masumura M., Hata R., Nishimura I., Uetsuki T., Sawada T., Yoshikawa K. Caspase-3 activation and inflammatory responses in rat hippocampus inoculated with a recombinant adenovirus expressing the Alzheimer amyloid precursor protein. Brain Res. Mol. Brain Res. 2000, 80:219-227.
39. Mc Donald J.M., Savva G.M., Brayne C., Welzel A.T., Forster G., Shankar G.M., Selkoe D.J., Ince P.G., Walsh D.M., Medical Research Council Cognitive Function and Ageing Study The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 2010, 133:1328-1341.
40. Murray A.J., Shewan D.A. Epac mediates cyclic AMP-dependent axon growth, guidance and regeneration. Mol. Cell. Neurosci. 2008, 38:578-588.
41. Murray A.J., Peace A.G., Shewan D.A. cGMP promotes neurite outgrowth and growth cone turning and improves axon regeneration on spinal cord tissue in combination with cAMP. Brain Res. 2009, 1294:12-21.
42. Necula M., Breydo L., Milton S., Kayed R., van der Veer W.E., Tone P., Glabe C.G. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 2007, 46:8850-8860.
43. Niewiadomska G., Baksalerska-Pazera M., Riedel G. Altered cellular distribution of phospho-tau proteins coincides with impaired retrograde axonal transport in neurons of aged rats. Ann. NY Acad. Sci. 2005, 1048:287-295.
44. Nishimura I., Uetsuki T., Dani S.U., Ohsawa Y., Saito I., Okamura H., Uchiyama Y., Yoshikawa K. Degeneration in vivo of rat hippocampal neurons by wild-type Alzheimer amyloid precursor protein overexpressed by adenovirus-mediated gene transfer. J. Neurosci. 1998, 18:2387-2398.
45. Oz M., Lorke D.E., Petroianu G.A. Methylene blue and Alzheimer's disease. Biochem. Pharmacol. 2009, 78:927-932.
46. Ozaki T., Li Y., Kikuchi H., Tomita T., Iwatsubo T., Nakagawara A. The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis. Biochem. Biophys. Res. Commun. 2006, 351:57-63.
47. Paglini G., Peris L., Mascotti F., Quiroga S., Caceres A. Tau protein function in axonal formation. Neurochem. Res. 2000, 25:37-42.
48. Plantman S., Patarroyo M., Fried K., Domogatskaya A., Tryggvason K., Hammarberg H., Cullheim S. Integrin-laminin interactions controlling neurite outgrowth from adult DRG neurons in vitro. Mol. Cell. Neurosci. 2008, 39:50-62.
49. Platt B. Metals, neurotoxicity and neurodegenerative disorders. Molecular and Supramolecular Bioinorganic Chemistry: Applications in Medical Sciences 2008, 69-81. Nova Science Publishers, New York. A.L.R. Merce, J. Felcman, M.A.L. Recio (Eds.).
50. Poppek D., Keck S., Ermak G., Jung T., Stolzing A., Ullrich O., Davies K.J., Grune T. Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem. J. 2006, 400:511-520.
51. Prasanthi R.J., Dasari B., Marwarha G., Larson T., Chen X., Geiger J.D., Ghribi O. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic. Biol. Med. 2010, 49:1212-1220.
52. Querfurth H.W., LaFerla F.M. Mechanisms of disease: Alzheimer's disease. N. Engl. J. Med. 2010, 326:329-344.
53. Quintanilla R.A., Matthews-Roberson T.A., Dolan P.J., Johnson G.V. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J. Biol. Chem. 2009, 284:18754-18766.
54. Raina A.K., Hochman A., Zhu X., Rottkamp C.A., Nunomura A., Siedlak S.L., Boux H., Castellani R.J., Perry G., Smith M.A. Abortive apoptosis in Alzheimer's disease. Acta Neuropathol. 2001, 101:305-310.
55. Ryan D., Drysdale A.J., Lafourcade C., Pertwee R.G., Platt B. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J. Neurosci. 2009, 29:2053-2063.
56. Ryder J., Su Y., Liu F., Li B., Zhou Y., Ni B. Divergent roles of GSK3 and CDK5 in APP processing. Biochem. Biophys. Res. Commun. 2003, 312:922-929.
57. Santos S.F., Pierrot N., Morel N., Gailly P., Sindic C., Octave J.N. Expression of human amyloid precursor protein in rat cortical neurons inhibits calcium oscillations. J. Neurosci. 2009, 29:4708-4718.
58. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
59. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27:2866-2875.
60. Sinha S., Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc. Natl Acad. Sci. USA 1999, 96:11049-11053.
61. Stadelmann C., Deckwerth T.L., Srinivasan A., Bancher C., Bruck W., Jellinger K., Lassmann H. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am. J. Pathol. 1999, 155:1459-1466.
62. Stamer K., Vogel R., Thies E., Mandelkow E., Mandelkow E.M. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 2002, 156:1051-1063.
63. Stoppelkamp S., Riedel G., Platt B. Culturing conditions determine neuronal and glial excitability. J. Neurosci. Meth. 2010, 194:132-138.
64. Stutzmann G.E. The pathogenesis of Alzheimers disease is it a lifelong "calciumopathy"?. Neuroscientist 2007, 13:546-559.
65. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 2005, 280:7614-7623.
66. Tominaga K., Uetsuki T., Ogura A., Yoshikawa K. Glutamate responsiveness enhanced in neurones expressing amyloid precursor protein. NeuroReport 1997, 8:2067-2072.
67. Tominaga-Yoshino K., Uetsuki T., Yoshikawa K., Ogura A. Neurotoxic and neuroprotective effects of glutamate are enhanced by introduction of amyloid precursor protein cDNA. Brain Res. 2001, 918:121-130.
68. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
69. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
70. Wang H.H., Li H.L., Liu R., Zhang Y., Liao K., Wang Q., Wang J.Z., Liu S.J. Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. J. Alzheimers Dis. 2010, 21:167-179.
71. Wang Z.F., Yin J., Zhang Y., Zhu L.Q., Tian Q., Wang X.C., Li H.L., Wang J.Z. Overexpression of tau proteins antagonizes amyloid-beta-potentiated apoptosis through mitochondria-caspase-3 pathway in N2a cells. J. Alzheimers Dis. 2010, 20:145-157.
72. Wischik C.M., Edwards P.C., Lai R.Y., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl Acad. Sci. USA 1996, 93:11213-11218.
73. Woodhouse A., Dickson T.C., West A.K., McLean C.A., Vickers J.C. No difference in expression of apoptosis-related proteins and apoptotic morphology in control, pathologically aged and Alzheimer's disease cases. Neurobiol. Dis. 2006, 22:323-333.
74. Yuan H., Zhai P., Anderson L.M., Pan J., Thimmapaya B., Koo E.H., Marquez-Sterling N.R. Recombinant adenovirus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons. J. Neurosci. Meth. 1999, 88:45-54.
75. Zhang Y., McLaughlin R., Goodyer C., LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J. Cell Biol. 2002, 156:519-529.